Sign In
Buy ANEB
$0.375
-0.0256 (-6.39%)
At Close: Jun 03, 2026
Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison
02:08am, Thursday, 12'th Mar 2026
Replimune Group (NASDAQ: REPL - Get Free Report) and Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare th
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
04:15pm, Thursday, 12'th Feb 2026
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
09:00am, Friday, 06'th Feb 2026
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next?
05:02am, Friday, 06'th Feb 2026
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s stock price dropped 13.6% on Thursday. The stock traded as low as $0.8031 and last traded at $0.8212. Approximately 42,620 shares were
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next?
04:12am, Friday, 06'th Feb 2026
Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s share price was down 13.6% during trading on Thursday. The company traded as low as $0.8031 and last traded at $0.8212. Approximately 4
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
09:00am, Thursday, 29'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
09:00am, Tuesday, 27'th Jan 2026
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer.
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
09:00am, Monday, 22'nd Dec 2025
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
04:05pm, Thursday, 13'th Nov 2025
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates.
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
04:05pm, Monday, 29'th Sep 2025
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
08:00am, Wednesday, 23'rd Jul 2025
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
04:05pm, Tuesday, 13'th May 2025
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
04:05pm, Friday, 14'th Feb 2025
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.
